Molecular Docking Analysis Reveals the Promising Role of Apigenin as a Potential Treatment for Neurological Disorders.
Journal
Clinical neuropharmacology
ISSN: 1537-162X
Titre abrégé: Clin Neuropharmacol
Pays: United States
ID NLM: 7607910
Informations de publication
Date de publication:
16 Sep 2024
16 Sep 2024
Historique:
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
13
9
2024
Statut:
aheadofprint
Résumé
Neurological disorders represent a significant global health challenge, necessitating the exploration of novel therapeutic agents. Apigenin, a natural flavonoid abundantly found in various plants, has garnered attention for its potential neuroprotective properties. In this study, we employed molecular docking simulations to investigate the interaction between apigenin and key molecular targets associated with neurological disorders. The molecular docking analysis focused on receptors implicated in neuroinflammation, oxidative stress, and neurotransmission regulation. Our results reveal a high binding affinity of apigenin towards critical targets, including GABA, mACh, nACh, NMDA, 5HTA, AMPA, insulin, and dopamine receptors. The findings suggest that apigenin may exert its neuroprotective effects through multifaceted mechanisms, including anti-inflammatory, antioxidant, and neurotransmission regulatory pathways. Additionally, the absence of adverse binding poses emphasizes the safety profile of apigenin. This molecular docking study provides valuable insights into the potential therapeutic role of apigenin in mitigating molecular pathways implicated in neurological disorders. Further in vitro and in vivo investigations are warranted to validate and elucidate the neuroprotective mechanisms of apigenin, paving the way for its development as a promising treatment option for various neurological conditions.
Identifiants
pubmed: 39268993
doi: 10.1097/WNF.0000000000000608
pii: 00002826-990000000-00097
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare.
Références
Salehi B, Venditti A, Sharifi-Rad M, et al. The therapeutic potential of apigenin. Int J Mol Sci 2019;20(6):1305. doi:10.3390/ijms20061305.
doi: 10.3390/ijms20061305
Ginwala R, Bhavsar R, Chigbu DI, et al. Potential role of flavonoids in treating chronic inflammatory diseases with a special focus on the anti-inflammatory activity of apigenin. Antioxidants (Basel) 2019;8(2):35. doi:10.3390/antiox8020035.
doi: 10.3390/antiox8020035
Dourado NS, Dos Santos Souza C, de Almeida MMA, et al. Neuroimmunomodulatory and neuroprotective effects of the flavonoid apigenin in in vitro models of neuroinflammation associated with Alzheimer's disease. Front Aging Neurosci 2020;12:119. doi:10.3389/fnagi.2020.00119.
doi: 10.3389/fnagi.2020.00119
Kim M, Jung J, Jeong NY, et al. The natural plant flavonoid apigenin is a strong antioxidant that effectively delays peripheral neurodegenerative processes. Anat Sci Int 2019;94(4):285–294.
Ayaz M, Sadiq A, Junaid M, et al. Flavonoids as prospective neuroprotectants and their therapeutic propensity in aging associated neurological disorders. Front Aging Neurosci 2019;11:155.
Vauzour D, Vafeiadou K, Rodriguez-Mateos A, et al. The neuroprotective potential of flavonoids: a multiplicity of effects. Genes Nutr 2008;3(3–4):115–126.
Liu W, Kong S, Xie Q, et al. Protective effects of apigenin against 1-methyl-4-phenylpyridinium ion-induced neurotoxicity in PC12 cells. Int J Mol Med 2015;35(3):739–746.
Pannu A, Sharma PC, Thakur VK, et al. Emerging role of flavonoids as the treatment of depression. Biomolecules 2021;11(12):1825.
Amin F, Ibrahim MAA, Rizwan-Ul-Hasan S, et al. Interactions of apigenin and safranal with the 5HT1A and 5HT2A receptors and behavioral effects in depression and anxiety: a molecular docking, lipid-mediated molecular dynamics, and in vivo analysis. Molecules 2022;27(24):8658. doi:10.3390/molecules27248658.
doi: 10.3390/molecules27248658
Alghamdi A, Almuqbil M, Alrofaidi MA, et al. Potential antioxidant activity of apigenin in the obviating stress-mediated depressive symptoms of experimental mice. Molecules 2022;27(24):9055.
Olayinka JN, Akawa OB, Ogbu EK, et al. Apigenin attenuates depressive-like behavior via modulating monoamine oxidase A enzyme activity in chronically stressed mice. Curr Res Pharmacol Drug Discov 2023;5:100161.
Yi L-T, Li J-M, Li Y-C, et al. Antidepressant-like behavioral and neurochemical effects of the citrus-associated chemical apigenin. Life Sci 2008;82(13–14):741–751.
Sachdeva P, Mehdi I, Kaith R, et al. Potential natural products for the management of autism spectrum disorder. Ibrain 2022;8(3):365–376.
Savino R, Medoro A, Ali S, et al. The emerging role of flavonoids in autism spectrum disorder: a systematic review. J Clin Med 2023;12(10):3520.
Abd Elazeem AH, Kotb HM, Mahmoud HA, et al. The ameliorative effect of apigenin or silymarin as add-on therapy to risperidone on valproic acid induced autism in albino rats: implication of oxidative stress, apoptosis and autophagy. Egypt J Hosp Med 2023;90(1):1245–1255.
Gnanaraj C, Sekar M, Fuloria S, et al. In silico molecular docking analysis of Karanjin against Alzheimer's and Parkinson's diseases as a potential natural lead molecule for new drug design, development and therapy. Molecules 2022;27(9):2834.
Mohan Sahoo B, Dinda SC, Ravi Kumar BVV, et al. Molecular docking study, green synthesis and pharmacological evaluation of 1, 3, 4-thiadiazole derivatives as potential antiepileptic agents. Mini Rev Med Chem 2013;13(14):2076–2081.
Zia SR, Wasim M, Ahmad S. Unlocking therapeutic potential of trigonelline through molecular docking as a promising approach for treating diverse neurological disorders. Metab Brain Dis 2023;38(8):2721–2733.
Broni E, Striegel A, Ashley C, et al. Molecular docking and dynamics simulation studies predict potential anti-ADAR2 inhibitors: implications for the treatment of cancer, neurological, immunological and infectious diseases. Int J Mol Sci 2023;24(7):6795.
Iqbal D, Rizvi SMD, Rehman MT, et al. Soyasapogenol-B as a potential multitarget therapeutic agent for neurodegenerative disorders: molecular docking and dynamics study. Entropy (Basel) 2022;24(5):593.
Lakey-Beitia J, Kumar DJ, Hegde ML, et al. Carotenoids as novel therapeutic molecules against neurodegenerative disorders: chemistry and molecular docking analysis. Int J Mol Sci 2019;20(22):5553.
Wang X, Yu Z, Dong F, et al. Clarifying the mechanism of apigenin against blood–brain barrier disruption in ischemic stroke using systems pharmacology. Mol Divers 2024;28:609–630. doi:10.1007/s11030-023-10607-9.
doi: 10.1007/s11030-023-10607-9
Siddique YH, Rahul, Ara G, et al. Beneficial effects of apigenin on the transgenic Drosophila model of Alzheimer's disease. Chem Biol Interact 2022;366:110120.
Saima, Anjum I, Mobashar A, et al. Spasmolytic and uroprotective effects of apigenin by downregulation of TGF-β and iNOS pathways and upregulation of antioxidant mechanisms: in vitro and in silico analysis. Pharmaceuticals (Basel) 2023;16(6):811.
Ahmad S, Rafiq H, Khan A, et al. Ameliorative effects of half-dose saffron and chamomile combination on psycho-endocrinological changes in a diabetic murine model. PloS One 2022;17(10):e0276236.
Ahmad S, Khan A, Tabassum S, et al. Co-administration of saffron and chamomile give additive effects of antidiabetic and antioxidant activity with <i > in vivo</i > augmentation of brain BDNF, acetylcholine levels and cognitive functions in streptozotocininduced diabetic rats. Curr Psychopharmacol 2022;11(1):56–69.
Ahmad S, Azhar A, Tikmani P, et al. A randomized clinical trial to test efficacy of chamomile and saffron for neuroprotective and anti-inflammatory responses in depressive patients. Heliyon 2022;8(10):e10774.